Document Detail

Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease.
MedLine Citation:
PMID:  20484828     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The JELIS trial examined the preventive effects of eicosapentaenoic acid (EPA) on coronary artery disease (CAD) in hypercholesterolemia. Previous investigators have reported that patients with peripheral artery disease (PAD) have a poor prognosis due to the potential risk for CAD. We conducted a subanalysis to examine whether the incidence of CAD was high in patients with PAD and whether EPA prevented the occurrence of CAD.
METHODS AND RESULTS: Of 18,645 the Japan EPA lipid intervention study (JELIS) patients, 223 had PAD (control group; complicated (n=77), newly diagnosed (n=29), EPA group; complicated (n=96), newly diagnosed (n=21)). We analyzed the incidence of major coronary events (MCE) in the 2 groups. Cox proportional hazard ratio adjusted for baseline risk factor levels was used to test differences between the 2 groups. The incidence of MCE in the control group was significantly higher in patients complicated with PAD and in those newly diagnosed with PAD than in patients without PAD (complicated: hazard ratio 1.97, P=0.039; newly diagnosed: hazard ratio 2.88, P=0.030). As for patients with PAD, the EPA group had a significantly lower MCE hazard ratio than the control group (hazard ratio 0.44, 95% confidence interval 0.19-0.97, P=0.041).
CONCLUSIONS: Subanalysis of the JELIS trial demonstrated that in patients with PAD the incidence of CAD was higher than in controls, and that EPA markedly reduced the occurrence of CAD in those patients.
Yuichi Ishikawa; Mitsuhiro Yokoyama; Yasushi Saito; Masunori Matsuzaki; Hideki Origasa; Shinichi Oikawa; Jun Sasaki; Hitoshi Hishida; Hiroshige Itakura; Toru Kita; Akira Kitabatake; Noriaki Nakaya; Toshiie Sakata; Kazuyuki Shimada; Kunio Shirato; Yuji Matsuzawa;
Related Documents :
9760288 - Reduction of recurrent ischemia with abciximab during continuous ecg-ischemia monitorin...
18586758 - Serum selenium and glutathione peroxidase concentrations in iranian patients with angio...
17694458 - Patients with non-st-elevation myocardial infarction and without chest pain are treated...
20210568 - Glucose monitoring by means of an intravenous microdialysis catheter technique.
22695238 - C-type natriuretic peptide is associated with the severity of crimean-congo hemorrhagic...
10406258 - Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-05-18
Journal Detail:
Title:  Circulation journal : official journal of the Japanese Circulation Society     Volume:  74     ISSN:  1347-4820     ISO Abbreviation:  Circ. J.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-30     Completed Date:  2010-10-19     Revised Date:  2011-02-18    
Medline Journal Info:
Nlm Unique ID:  101137683     Medline TA:  Circ J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  1451-7     Citation Subset:  IM    
Kakogawa Municipal Hospital, Kakogawa, Japan.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Artery Disease / drug therapy*,  etiology,  prevention & control
Eicosapentaenoic Acid / pharmacology*
Middle Aged
Peripheral Vascular Diseases / complications*
Protective Agents
Treatment Outcome
Reg. No./Substance:
0/Protective Agents; 1553-41-9/Eicosapentaenoic Acid
Comment In:
Circ J. 2010 Jul;74(7):1298-9   [PMID:  20558888 ]
Circ J. 2010 Nov 25;74(12):2786; author reply 2787   [PMID:  21048326 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relationship between oral amiodarone and inappropriate therapy from an implantable cardioverter defi...
Next Document:  Mechanical properties of a resin-modified glass ionomer cement for luting: effect of adding spherica...